Navigation Links
Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
Date:1/4/2012

BLUE BELL, Pa., Jan. 4, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), which is revolutionizing vaccines to fight cancers and infectious diseases, announced today that it has promoted Niranjan Y. Sardesai, Ph.D., from Senior Vice President Research and Development to Chief Operating Officer. In his expanded role, Dr. Sardesai will be responsible for corporate and business development for the company in addition to continuing to oversee research and development. Inovio also announced the retirement of Kevin W. Rassas, former Senior Vice President Business Development.

Dr. J. Joseph Kim, President and CEO of Inovio Pharmaceuticals, said, "Niranjan brings to the COO position a strong combination of strategic business, transactional, and technical skills and broad operating experience. He has overseen the integration, development, and growth of Inovio's pipeline through the advancement of its proprietary technology as well as licensing and M&A efforts. We are pleased to have him assume this broader responsibility to help guide and execute Inovio's business plan to develop important new vaccines. Kevin played a vital role in the formative years of our predecessor company, VGX Pharmaceuticals, bringing big Pharma management experience to an entrepreneurial environment, and subsequently in advancing Inovio's key business relationships. We thank him for his contribution and commitment to Inovio and wish him the very best in the future."

Dr. Sardesai has broad operating and consulting experience in biotechnology and pharmaceuticals. He joined VGX Pharmaceuticals as VP Research and Development in 2006, was promoted to SVP R&D in 2007 and, with the merger of VGX with Inovio in June 2009, became SVP Research & Development of the merged company. Dr. Sardesai is responsible for leading the company's product development programs in infectious disease and cancer vaccines and vaccine delivery systems. He has secured ov
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Inovio Pharmaceuticals DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study
2. Inovio Pharmaceuticals Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial
3. Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
4. Inovio Pharmaceuticals Enters Phase II Clinical Trial with SynCon™ DNA Vaccine for Cervical Dysplasia Caused by HPV
5. Inovio Pharmaceuticals Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease
6. Inovio Pharmaceuticals to Present at 13th Annual BIO CEO & Investor Conference
7. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
11. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014 Over the last decade, the ... rising R&D budgets and increased acceptance of new filtration ... and biotechnology industries are also catalyzing the growth of ... is expected to grow at a strong CAGR during ... be worth $2,532.6 million by 2019. The market is ...
(Date:9/30/2014)... 30, 2014 Follow us on ... each type of cholesterol carrier or lipoprotein in the ... excessive cholesterol levels in the body, especially along the ... heart attack and other cardiovascular disorders. Cardiovascular Diseases (CVD) ... for cholesterol levels on a regular basis, to assess ...
(Date:9/30/2014)... Sept. 30, 2014 CORD:USE Cord Blood Bank ... that it has entered into an Equity and Exclusive ... has licensed a series of patented technologies for the isolation ... clinical applications.  Tianhe is performing Phase I/II clinical trials ... Spain using Tianhe,s Stem Cell Educator Therapy ...
(Date:9/30/2014)... Genedata, a leading provider ... and related life science research, today announced ... Selector as its host-pathogen data analysis platform ... a European consortium dedicated to improving the ... anti-fungal drug therapies. Genedata Selector supports this ...
Breaking Biology Technology:Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3
... Gore PharmBIO Products Launches Unique Online Configurator For the ... ... 24 Gore PharmBIO Products has,launched an industry first -- ... and configuring fluid,assemblies for biopharmaceutical manufacturers., The GORE(TM) STA-PURE(SM) ...
... NEOG ) announced today that its revenues for ... increased 26% from the previous year,s first,quarter to $28,805,000. ... $3,011,000 to $3,733,000, or to $0.25 per share in ... Neogen,s first quarter revenues, net income, and earnings per ...
... to new screening platform for antibody therapeutics, ... ROG),announced today that it has completed the acquisition ... warrants of ARIUS Research (TSX: ARI). On,September 19th, ... of,Arrangement previously approved by the security holders and ...
Cached Biology Technology:Gore's Legacy of Innovation Extends From Products to Processes 2Gore's Legacy of Innovation Extends From Products to Processes 3Neogen Reports 26% Increase in Revenues 2Neogen Reports 26% Increase in Revenues 3Neogen Reports 26% Increase in Revenues 4Neogen Reports 26% Increase in Revenues 5Neogen Reports 26% Increase in Revenues 6Roche completes acquisition of ARIUS 2
(Date:9/30/2014)... professor and Howard Hughes Medical Institute investigator, and ... recipients in the 2014 round of grants from ... BRAIN (Brain Research through Advancing Innovative Neurotechnologies) Initiative ... September 30, provides more than $3 million in ... , The BRAIN Initiative, launched last year, is ...
(Date:9/30/2014)... news release is available in German . ... are among the most expensive foods in the world. Because ... find them. But the distinctive smell of truffles is not ... French scientists under the direction of the Goethe University Frankfurt ... produced by soil bacteria which are trapped inside truffle fruiting ...
(Date:9/30/2014)... Here,s some hope: A new research report published in ... , explains how scientists developed a synthetic version ... embryo development in human and mouse eggs similar to ... cell during fertilization. , "We believe that the results ... our understanding of human fertilization by providing a precise ...
Breaking Biology News(10 mins):Salk scientists receive $3 million for BRAIN Initiative grant 2On the trail of the truffle flavor 2Synthetic sperm protein raises the chance for successful in vitro fertilization 2
... the Universitat Autònoma de Barcelona has developed new miniature ... size and thickness as a fingernail and reduce the ... or a few hours, depending on each chain. These ... from paternity tests and identifying people to detecting genetically ...
... Roundup® is widely used to eradicate weeds. But a ... finds that the chemical may be eradicating much more ... Relyea found that Roundup®, the second most commonly applied ... amphibians. This field experiment is one of the most ...
... of mouse actually shrink during the winter, causing the mice ... new study found. , The results showed that, during the ... ?the mental map that helps them remember important places in ... to show seasonal changes in the structure and the functioning ...
Cached Biology News:New miniaturised chip dramatically reduces time taken for DNA analysis 2New miniaturised chip dramatically reduces time taken for DNA analysis 3Roundup®highly lethal to amphibians, finds University of Pittsburgh researcher 2Mice brains shrink during winter, impairing some learning and memory 2Mice brains shrink during winter, impairing some learning and memory 3
Antibody specific for histone H3 acetylated at any of the five N-terminal lysine residues. Rabbit polyclonal serum. Antigen: Synthetic peptide derived from histone H3 N-terminal region, mulitpliy...
The FailSafe™ PROBES Real-Time PCR System enables rapid, precise optimization of PCR experiments in which the product is detected using fluorescent target-specific labeled probes....
NuParaffin Kit Application: Flow Cytometry Reactivity: Human...
Immunofixation Gel Kit, requires IF100 Reactivity: Human Applications: Immunofixation ...
Biology Products: